Company

Eli Lilly

Eli Lilly has 79 drugs tracked on RxWires: 5 post-market, 7 approved, 14 in Phase 3, 3 in Phase 2/3, 21 in Phase 2, 2 in Phase 1/2, 27 in Phase 1.

Ticker: LLY

Pipeline

Drug	Phase	Indication
Lispro mix 75/25	Post-Market	Type 2 Diabetes
Insulin Lispro-aabc	Post-Market	Diabetes Mellitus, Type 2
Olanzapine Hydrochloride	Post-Market	Schizophrenic Disorders
Abciximab	Post-Market	Shock, Cardiogenic
Dulaglutide	Post-Market	Type 2 Diabetes
DIETHYLSTILBESTROL	Approved
HISTALOG	Approved
GLUCAGON	Approved
EMGALITY	Approved
MOUNJARO	Approved
CINOBAC	Approved
CYMBALTA	Approved
Lepodisiran	Phase 3	Atherosclerosis
Orforglipron	Phase 3	Overweight
teriparatide	Phase 3	Osteoporosis, Post-Menopausal
Olomorasib	Phase 3	Carcinoma, Non-Small-Cell Lung
Bamlanivimab	Phase 3	COVID-19
5 mg Tadalafil	Phase 3	Benign Prostate Hyperplasia
Adalimumab	Phase 3	Rheumatoid Arthritis
Baricitinib	Phase 3	Atopic Dermatitis
Eloralintide	Phase 3	Osteoarthritis
Human Insulin Inhalation Powder	Phase 3	Diabetes Mellitus, Type 1
Rapid-Acting Intramuscular Olanzapine	Phase 3	Schizophrenia
Prasugrel	Phase 3	Sickle Cell Disease
simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder	Phase 3	Diabetes Mellitus, Type 2
Retatrutide	Phase 3	Obesity
LY3819253	Phase 2/3	COVID-19
Insulin glargine	Phase 2/3	Diabetes Mellitus, Type 1
Evorpacept (ALX148)	Phase 2/3	Gastric Cancer
LY3537031	Phase 2	Irritable Bowel Syndrome
Bimagrumab	Phase 2	Heart Failure, Diastolic
Brenipatide	Phase 2	Major Depressive Disorder
LY3016859 ISA	Phase 2	Osteoarthritis, Knee
Solbinsiran	Phase 2	Severe Hypertriglyceridemia
LY4268989	Phase 2	Ulcerative Colitis (UC)
LY3857210	Phase 2	Osteoarthritis
pemetrexed	Phase 2	Non-Small Cell Lung Cancer
Capecitabine	Phase 2	Renal Cell Carcinoma
naveglitazar	Phase 2	Diabetes Mellitus, Non-Insulin-Dependent
Enzastaurin	Phase 2	Lung Cancer
insulin	Phase 2	Diabetes Mellitus, Type 1
Cetuximab	Phase 2	Colorectal Neoplasms
120 mg LY2784544	Phase 2	Neoplasms, Hematologic
Ramucirumab	Phase 2	Gastric Adenocarcinoma
LY3023414	Phase 2	Prostate Cancer Metastatic
Pembrolizumab	Phase 2	Non-small Cell Lung Cancer Stage IB
gemcitabine	Phase 2	Non-Small Cell Lung Cancer
Galcanezumab	Phase 2	Migraine
Imlunestrant	Phase 2	Breast Neoplasms
Osimertinib	Phase 2	Non Small Cell Lung Cancer
LY3537982	Phase 1/2	Carcinoma, Non-Small-Cell Lung
Pirtobrutinib	Phase 1/2	Chronic Lymphocytic Leukemia
LY3971297	Phase 1	Heart Failure
LY4256984	Phase 1	ALS (Amyotrophic Lateral Sclerosis)
LY4214835	Phase 1	Neoplasms
LY4405094	Phase 1	Alzheimer Disease
LY4515100 via SAD	Phase 1
LY3549492	Phase 1	Obesity
LY2605541	Phase 1	Healthy Volunteers
VXCO-100	Phase 1	SARS-CoV
LY2928057	Phase 1	Renal Insufficiency, Chronic
LY4005130	Phase 1	Healthy
[14C]-LY3473329	Phase 1	Healthy
Pegilodecakin	Phase 1	Healthy Adult Subjects
Olomorasib test	Phase 1	Healthy Volunteers
LY2875358	Phase 1	Advanced Cancer
LY2801653	Phase 1	Cancer
LY4292009	Phase 1	Healthy
MORF-057	Phase 1	Healthy Volunteers
BioChaperone insulin lispro	Phase 1	Type 1 Diabetes Mellitus
LY4064809	Phase 1	Healthy
LY2189265	Phase 1	Diabetes Mellitus, Type 2
LY4178256	Phase 1	Healthy Volunteers
[Ac-225]-PSMA-62 (mCRPC)	Phase 1	Prostate Cancer
LY3463251	Phase 1	Healthy
LY4050784	Phase 1	Metastatic Solid Tumor
LY4336619	Phase 1	Endometrial Neoplasms
LY3981314	Phase 1	Hepatitis Autoimmune Disease
LY4152199 - IV	Phase 1	Lymphoma, Non-Hodgkin

Latest

Follow Eli Lilly on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.

Follow free

Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.